Literature DB >> 24395820

Transcriptional profiling of melanoma sentinel nodes identify patients with poor outcome and reveal an association of CD30(+) T lymphocytes with progression.

Viviana Vallacchi1, Elisabetta Vergani, Chiara Camisaschi, Paola Deho, Antonello D Cabras, Marialuisa Sensi, Loris De Cecco, Niccolò Bassani, Federico Ambrogi, Antonino Carbone, Federica Crippa, Barbara Vergani, Paola Frati, Flavio Arienti, Roberto Patuzzo, Antonello Villa, Elia Biganzoli, Silvana Canevari, Mario Santinami, Chiara Castelli, Licia Rivoltini, Monica Rodolfo.   

Abstract

Sentinel lymph nodes set the stance of the immune system to a localized tumor and are often the first site to be colonized by neoplastic cells that metastasize. To investigate how the presence of neoplastic cells in sentinel lymph nodes may trigger pathways associated with metastatic progression, we analyzed the transcriptional profiles of archival sentinel node biopsy specimens obtained from melanoma patients. Biopsies from positive nodes were selected for comparable tumor infiltration, presence or absence of further regional node metastases, and relapse at 5-year follow-up. Unsupervised analysis of gene expression profiles revealed immune response to be a major gene ontogeny represented. Among genes upregulated in patients with progressing disease, the TNF receptor family member CD30/TNFRSF8 was confirmed in biopsy specimens from an independent group of patients. Immunohistochemical analysis revealed higher numbers of CD30(+) lymphocytes in nodes from progressing patients compared with nonprogressing patients. Phenotypic profiling demonstrated that CD30(+) lymphocytes comprised a broad population of suppressive or exhausted immune cells, such as CD4(+)Foxp3(+) or PD1(+) subpopulations and CD4(-)CD8(-) T cells. CD30(+) T lymphocytes were increased in peripheral blood lymphocytes of melanoma patients at advanced disease stages. Our findings reinforce the concept that sentinel nodes act as pivotal sites for determining progression patterns, revealing that the presence of CD30(+) lymphocytes at those sites associate positively with melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24395820     DOI: 10.1158/0008-5472.CAN-13-1672

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Computational Immune Monitoring Reveals Abnormal Double-Negative T Cells Present across Human Tumor Types.

Authors:  Allison R Greenplate; Daniel D McClanahan; Brian K Oberholtzer; Deon B Doxie; Caroline E Roe; Kirsten E Diggins; Nalin Leelatian; Megan L Rasmussen; Mark C Kelley; Vivian Gama; Peter J Siska; Jeffrey C Rathmell; P Brent Ferrell; Douglas B Johnson; Jonathan M Irish
Journal:  Cancer Immunol Res       Date:  2018-11-09       Impact factor: 11.151

2.  Immune checkpoints: Cytotoxic T-lymphocyte antigen 4 and programmed cell death protein 1 in breast cancer surgery.

Authors:  Agnieszka Kolacinska; Barbara Cebula-Obrzut; Lukasz Pakula; Justyna Chalubinska-Fendler; Alina Morawiec-Sztandera; Zofia Pawlowska; Izabela Zawlik; Zbigniew Morawiec; Dorota Jesionek-Kupnicka; Piotr Smolewski
Journal:  Oncol Lett       Date:  2015-06-04       Impact factor: 2.967

Review 3.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

4.  Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

Authors:  Andreas A Hombach; Gunter Rappl; Hinrich Abken
Journal:  Mol Ther       Date:  2019-06-19       Impact factor: 11.454

5.  Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis.

Authors:  Nicolas Jacquelot; María Paula Roberti; David P Enot; Sylvie Rusakiewicz; Michaela Semeraro; Sarah Jégou; Camila Flores; Lieping Chen; Byoung S Kwon; Christophe Borg; Benjamin Weide; François Aubin; Stéphane Dalle; Holbrook Kohrt; Maha Ayyoub; Guido Kroemer; Aurélien Marabelle; Andréa Cavalcanti; Alexander Eggermont; Laurence Zitvogel
Journal:  J Invest Dermatol       Date:  2016-01-29       Impact factor: 8.551

6.  microRNA Expression in Sentinel Nodes from Progressing Melanoma Patients Identifies Networks Associated with Dysfunctional Immune Response.

Authors:  Viviana Vallacchi; Chiara Camisaschi; Matteo Dugo; Elisabetta Vergani; Paola Deho; Ambra Gualeni; Veronica Huber; Annunziata Gloghini; Andrea Maurichi; Mario Santinami; Marialuisa Sensi; Chiara Castelli; Licia Rivoltini; Monica Rodolfo
Journal:  Genes (Basel)       Date:  2016-12-14       Impact factor: 4.096

Review 7.  Systematic evaluation of immune regulation and modulation.

Authors:  David F Stroncek; Lisa H Butterfield; Michael A Cannarile; Madhav V Dhodapkar; Tim F Greten; Jean Charles Grivel; David R Kaufman; Heidi H Kong; Firouzeh Korangy; Peter P Lee; Francesco Marincola; Sergio Rutella; Janet C Siebert; Giorgio Trinchieri; Barbara Seliger
Journal:  J Immunother Cancer       Date:  2017-03-21       Impact factor: 13.751

8.  Characterization of the Microenvironment in Positive and Negative Sentinel Lymph Nodes from Melanoma Patients.

Authors:  Meriem Messaoudene; Aurélie Périer; Giulia Fregni; Emmanuelle Neves; Laurence Zitvogel; Isabelle Cremer; Johan Chanal; Xavier Sastre-Garau; Lydia Deschamps; Eduardo Marinho; Frederique Larousserie; Eve Maubec; Marie-Françoise Avril; Anne Caignard
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

9.  Immune response markers in sentinel nodes may predict melanoma progression.

Authors:  Monica Rodolfo; Chiara Castelli; Licia Rivoltini
Journal:  Oncoimmunology       Date:  2014-04-15       Impact factor: 8.110

10.  Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.

Authors:  Johan Falkenius; Hemming Johansson; Rainer Tuominen; Marianne Frostvik Stolt; Johan Hansson; Suzanne Egyhazi Brage
Journal:  BMC Cancer       Date:  2017-08-29       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.